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Background
The identification of molecular alterations that trigger
Wilms tumor (WT) development is crucial to understand-
ing the tumorigenesis of this malignancy. Currently, it is
estimated that WTX and WT1 genomic losses together
with CTNNB1 point mutations occur in about 30% of
WTs. However, the majority of cases remain without any
identified driver mutation. Results from a previous study
by our group pointed to APC and PLCG2 as candidate
genes altered in WT [1]. Given the advent of modern
DNA sequencing technologies, it is now feasible to evalu-
ate large genomic regions spanning complete genes (exons
and introns), allowing the description of the mutation pat-
terns occurring in tumor cells. Thus, the aim of this study
was to identify point mutations and indels in the complete
sequence of APC, CTNNB1, WT1, WTX and PLCG2
genes in order to characterize both the exonic mutational
spectrum and the intronic nucleotide substitution pattern.
Material and methods
The complete genomic regions of the selected genes, span-
ning a total of 430 kb, were amplified by long-range PCR
in 15 WTs and 3 non-neoplasic control samples, giving a
total of 60 amplicons per sample (10 kb on average). The
resulting amplicons were mixed at equimolar concentra-
tions and, for each sample, the Ion PGM library prepara-
tion protocol was performed. The libraries of the 18 bar-
coded samples were combined in four sequencing pools
that were individually submitted to an Ion PGM™
Sequencer run on an Ion 316™ Chip. Point mutation and
indels not present in the non-neoplasic controls were
selected for capillary sequencing validation. The validated
alterations were screened in an independent group of 39
WT and 96 normal control samples.
Results
For the 15 tumors and 3 normal controls, we obtained
400,000 sequences per sample on average (350× mean tar-
get coverage). At the exonic regions, four out of the four
identified missense alterations were validated. None of the
37 identified indels could be confirmed, probably due to
indel errors generated by the Ion PGM platform [2].
Three of the four missense alterations were not identified
in any of the 99 controls, and therefore were classified as
possibly associated with WT: two at APC (Ile2541Val and
Met1413Val) and one at PLCG2 (Asn946Ser). No point
mutation was observed for WT1 and CTNNB1 genes. In
the intronic regions, the somatic substitution pattern was
evaluated by classifying the tumor’s substitutions in two
groups: single nucleotide polymorphisms (SNPs) (altera-
tions also present in normal samples, dbSNP and
1000genomes) and somatic substitutions (remaining
alterations). A general trend in the somatic base substitu-
tion pattern was observed, with the tumors presenting an
over-representation of G:C>A:T changes (P >0.001) and a
reduction of A:T>G:C changes (P >0.001) when compared
to the SNP variants. Regarding the frequency of the other
classes of somatic substitutions, a wide variation was
observed among the different tumors.
Conclusions
This study provides insights into the spectrum of WT sub-
stitution mutations occurring in exonic and intronic
regions of five previously associated genes, revealing a low
frequency of point mutations in the coding sequence of
these genes and a general over-representation of somatic
G:C>A:T transitions.
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